Charmingly eccentric, full of personality, and designed for maximum reader engagement
OnTarget Trial Reveals Promising Results for Breast Cancer Patients
Adult patients with breast cancer are a prespecified subgroup of the recently conducted OnTarget trial evaluating crofelemer for prophylaxis of cancer therapy-related diarrhea. The results of this trial have been submitted to a relevant oncology conference in San Francisco, CA.
Jaguar Health, Inc. announced that the analysis of the prespecified subgroup of adult patients with breast cancer from the Phase 3 OnTarget trial indicate that crofelemer achieved statistical significance in this subgroup. Patients with breast cancer made up a significant portion of the participants in this groundbreaking prophylactic clinical trial.
In this unprecedented study, nearly 180 of the 287 participants had breast cancer and were receiving targeted therapy with or without standard chemotherapy. The results of this trial are promising for the management of cancer therapy-related diarrhea in breast cancer patients.
How Does This Impact Me?
For individuals diagnosed with breast cancer, the results of the OnTarget trial offer hope for a potential new treatment option to manage therapy-related diarrhea. Crofelemer could provide relief for patients undergoing targeted therapy, improving their quality of life during cancer treatment.
How Does This Impact the World?
The findings of the OnTarget trial have the potential to revolutionize the management of cancer therapy-related diarrhea not only for breast cancer patients but for all individuals with solid tumors receiving targeted therapy. This innovative approach could lead to better outcomes and improved patient care in oncology.
Conclusion
The results of the OnTarget trial in the subgroup of adult patients with breast cancer demonstrate the efficacy of crofelemer in managing cancer therapy-related diarrhea. This breakthrough could have a significant impact on the treatment and quality of life for individuals undergoing targeted therapy for solid tumors, ushering in a new era of care in oncology.
